keyword
https://read.qxmd.com/read/38516874/the-potential-for-improved-outcomes-in-the-prevention-and-therapy-of-diabetic-kidney-disease-through-stacking-of-drugs-from-different-classes
#21
REVIEW
David S H Bell, Terri Jerkins
Aggressive therapy of diabetic kidney disease (DKD) can not only slow the progression of DKD to renal failure but, if utilized at an early enough stage of DKD, can also stabilize and/or reverse the decline in renal function. The currently recognized standard of therapy for DKD is blockade of the renin-angiotensin system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). However, unless utilized at a very early stage, monotherapy with these drugs in DKD will only prevent or slow the progression of DKD and will neither stabilize nor reverse the progression of DKD to renal decompensation...
March 22, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38516472/nephrological-detrimental-impacts-resulting-from-novel-immunotherapy-drugs-used-in-the-treatment-of-cancer-a-systematic-review
#22
REVIEW
Amisha Jaiswal, Kainaat Shergill, Kusalik Boppana, Naiela E Almansouri, Saloni Bakkannavar, Youmna Faheem, Tuheen Sankar Nath
The most recent advancements in cancer therapy center on efficiently and conveniently enhancing a patient's natural immune system. Immune checkpoint inhibitors (ICIs) are antibodies that target cytotoxic thymus (T) lymphocyte antigen-4 (CTLA-4) and its receptor. They function by stimulating T-cell activity against malignancies. Immune-related adverse events (irAEs) are a distinct class of inflammatory side effects that are specific to a given organ. Antineoplastic medications can impact any part of the kidney, leading to the development of proteinuria, hypertension, electrolyte abnormalities, glomerulonephritis, and both acute and chronic interstitial nephritis...
February 2024: Curēus
https://read.qxmd.com/read/38515385/physician-perceptions-attitudes-and-strategies-towards-implementing-guideline-directed-medical-therapy-in-heart-failure-with-reduced-ejection-fraction-a-survey-of-the-heart-failure-association-of-the-esc-and-the-esc-council-for-cardiology-practice
#23
JOURNAL ARTICLE
Gianluigi Savarese, Felix Lindberg, Ruxandra M Christodorescu, Marc Ferrini, Thomas Kumler, Konstantinos Toutoutzas, Giuseppe Dattilo, Antoni Bayes-Genis, Brenda Moura, Offer Amir, Mark C Petrie, Petar Seferovic, Ovidiu Chioncel, Marco Metra, Andrew J S Coats, Giuseppe M C Rosano
AIMS: Recent guidelines recommend four core drug classes (renin-angiotensin system/angiotensin receptor-neprilysin inhibitor [RASi/ARNi], beta-blocker, mineralocorticoid receptor antagonist [MRA], and sodium-glucose cotransporter 2 inhibitor [SGLT2i]) for the pharmacological management of heart failure (HF) with reduced ejection fraction (HFrEF). We assessed physicians' perceived (i) comfort with implementing the recent HFrEF guideline recommendations; (ii) status of guideline-directed medical therapy (GDMT) implementation; (iii) use of different GDMT sequencing strategies; and (iv) barriers and strategies for achieving implementation...
March 22, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38514212/myocardial-fibrosis-in-right-heart-dysfunction
#24
JOURNAL ARTICLE
Lucia Agoston-Coldea, Andra Negru
Cardiac fibrosis, associated with right heart dysfunction, results in significant morbidity and mortality. Stimulated by various cellular and humoral stimuli, cardiac fibroblasts, macrophages, CD4+ and CD8+ T cells, mast and endothelial cells promote fibrogenesis directly and indirectly by synthesizing numerous profibrotic factors. Several systems, including the transforming growth factor-beta and the renin-angiotensin system, produce type I and III collagen, fibronectin and α-smooth muscle actin, thus modifying the extracellular matrix...
2024: Advances in Clinical Chemistry
https://read.qxmd.com/read/38513737/clinical-characteristics-treatment-trajectories-and-outcome-of-patients-with-dilated-cardiomyopathy-in-a-national-heart-failure-registry
#25
JOURNAL ARTICLE
Samuela Carigi, Piero Gentile, Mauro Gori, Denitza Tinti, Luisa De Gennaro, Giuseppe Leonardi, Francesco Orso, Anna Rita Felici, Maria Rosaria Catalano, Marina Floresta, Vittoria Rizzello, Donata Lucci, Lucio Gonzini, Renata De Maria, Marco Marini
BACKGROUND: Available data on the clinical characteristics and prognosis of patients with heart failure (HF) due to dilated cardiomyopathy (DCM) derive mainly from tertiary care centres for cardiomyopathies or from drug trial sub-studies, which may entail a referral bias. METHODS: From 2008 to 2021, we enrolled in a nationwide HF Registry 1886 DCM patients and 3899 with ischemic heart disease (IHD). RESULTS: Patients with DCM were younger, more often female, had more commonly recent onset HF, left bundle branch block, and showed higher LV end-diastolic volume and lower LVEF than IHD...
March 19, 2024: International Journal of Cardiology
https://read.qxmd.com/read/38513622/treatment-of-chronic-heart-failure-in-advanced-chronic-kidney-disease-the-haka-multicenter-retrospective-real-world-study
#26
JOURNAL ARTICLE
Borja Quiroga, Alberto Ortiz, Sara Núñez, Maria Kislikova, Silvia González Sanchidrián, José Jesús Broseta, Zoila Stany Albines, Beatriz Escamilla Cabrera, Yaiza Rivero Viera, David Rodriguez Santarelli, Laura Salanova Villanueva, Francisca Lopez Rodriguez, Barbara Cancho Castellano, María Ibáñez Cerezon, Carmen Patricia Gutierrez Rivas, Nuria Aresté, Belén Campos Gutiérrez, Ana Ródenas Gálvez, Maria Constanza Glucksmann Pizá, Sagrario Balda Manzanos, Amparo Soldevila, Lucía Rodríguez Gayo, Esperanza Moral Berrio, Mayra Ortega Diaz, Sandra Beltrán Catalán, Adriana Puente García, Miguel Ángel Rojas, R Haridian Sosa Barrios, Henar Santana Zapatero, Gema Rangel Hidalgo, Ana Maria Martinez Canet, Javier Díez
INTRODUCTION: Chronic heart failure (HF) has high rates of mortality and hospitalization in patients with advanced chronic kidney disease (aCKD). However, randomized clinical trials have systematically excluded aCKD population. We have investigated current HF therapy in patients receiving clinical care in specialized aCKD units. METHODS: The Heart And Kidney Audit (HAKA) was a cross-sectional and retrospective real-world study including outpatients with aCKD and HF from 29 Spanish centers...
March 21, 2024: Cardiorenal Medicine
https://read.qxmd.com/read/38513618/management-of-hyperkalemia-in-raasi-strategies-to-maintain-chronic-kidney-disease-patients-with-type-ii-diabetes-on-therapy
#27
REVIEW
Humaira A Mahmud, Biff F Palmer
BACKGROUND: According to the Centers for Disease Control and Prevention (CDC), diabetes affects approximately 37.3 million individuals in the United States (US), with another estimated 96 million people having a prediabetic state. Furthermore, one or two out of three adult Americans exhibit metabolic syndrome or an insulin-resistant state, depending on their age group. SUMMARY: Chronic Kidney Disease (CKD) represents a complication often associated with T2D or the insulin-resistant condition, typically identifiable through proteinuria...
March 21, 2024: Cardiorenal Medicine
https://read.qxmd.com/read/38511994/renin-levels-and-angiotensin-ii-responsiveness-in-vasopressor-dependent-hypotension
#28
JOURNAL ARTICLE
Emily J See, Anis Chaba, Sofia Spano, Akinori Maeda, Caroline Clapham, Louise M Burrell, Jasmine Liu, Monique Khasin, Grace Liskaser, Glenn Eastwood, Rinaldo Bellomo
OBJECTIVES: The relationship between renin levels, exposure to renin-angiotensin system (RAS) inhibitors, angiotensin II (ANGII) responsiveness, and outcome in patients with vasopressor-dependent vasodilatory hypotension is unknown. DESIGN: We conducted a single-center prospective observational study to explore whether recent RAS inhibitor exposure affected baseline renin levels, whether baseline renin levels predicted ANGII responsiveness, and whether renin levels at 24 hours were associated with clinical outcomes...
March 21, 2024: Critical Care Medicine
https://read.qxmd.com/read/38511310/atrial-septal-defect-pulmonary-arterial-hypertension-and-diastolic-left-heart-failure-when-3-players-come-into-the-game
#29
JOURNAL ARTICLE
Tobias Rutz, John-David Aubert, Maurice Beghetti, Eric Eeckhout, Olivier Muller, Judith Bouchardy, Patrick Yerly
No abstract text is available yet for this article.
March 21, 2024: Circulation. Heart Failure
https://read.qxmd.com/read/38510448/podocyte-number-and-glomerulosclerosis-indices-are-associated-with-the-response-to-therapy-for-primary-focal-segmental-glomerulosclerosis
#30
JOURNAL ARTICLE
Natasha de Zoysa, Kotaro Haruhara, David J Nikolic-Paterson, Peter G Kerr, Jonathan Ling, Sarah E Gazzard, Victor G Puelles, John F Bertram, Luise A Cullen-McEwen
Corticosteroid therapy, often in combination with inhibition of the renin-angiotensin system, is first-line therapy for primary focal and segmental glomerulosclerosis (FSGS) with nephrotic-range proteinuria. However, the response to treatment is variable, and therefore new approaches to indicate the response to therapy are required. Podocyte depletion is a hallmark of early FSGS, and here we investigated whether podocyte number, density and/or size in diagnostic biopsies and/or the degree of glomerulosclerosis could indicate the clinical response to first-line therapy...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38509679/targeting-hypertension-a-review-on-pathophysiological-factors-and-treatment-strategies
#31
JOURNAL ARTICLE
Ruhani Raj, Minakshi Garg, Anupreet Kaur
Hypertension is one of the primary causes of cardiovascular diseases and death, with a higher prevalence in low- and middle-income countries. The pathophysiology of hypertension remains complex, with 2% to 5% of patients having underlying renal or adrenal disorders. The rest are referred to as essential hypertension, with derangements in various physiological mechanisms potentially contributing to the development of essential hypertension. Hypertension elevates the risk of cardiovascular disease (CVD) events (coronary heart disease, heart failure, and stroke) and mortality...
March 20, 2024: Current Hypertension Reviews
https://read.qxmd.com/read/38509149/plasma-renin-as-a-novel-prognostic-biomarker-of-sepsis-associated-acute-respiratory-distress-syndrome
#32
JOURNAL ARTICLE
Anjali Chakradhar, Rebecca M Baron, Mayra Pinilla Vera, Prasad Devarajan, Lakhmir Chawla, Peter C Hou
Sepsis-associated acute respiratory distress syndrome (ARDS) is a life-threatening condition in critical care medicine for which there is a substantial need for early prognostic biomarkers of outcome. The present study seeks to link plasma renin levels and 30-day mortality in sepsis-associated ARDS patients treated at our institution. The Registry of Critical Illness (RoCI) prospectively enrolled patients from the intensive care units (ICU) within a single academic medical center, and a convenience sample of patients with sepsis-associated ARDS was analyzed from this cohort...
March 20, 2024: Scientific Reports
https://read.qxmd.com/read/38508877/renin-angiotensin-aldosterone-system-blockers-effect-in-chronic-kidney-disease-progression-in-hypertensive-elderly-patients-without-proteinuria-proercan-trial
#33
JOURNAL ARTICLE
A M García-Prieto, Ú Verdalles, A P de José, D Arroyo, I Aragoncillo, D Barbieri, R E Camacho, M Goicoechea
INTRODUCTION: Evidence about nefroprotective effect with RAAS blockers in elderly patients with chronic kidney disease (CKD) without proteinuria is lacking. The primary outcome of our study is to evaluate the impact of RAAS blockers in CKD progression in elderly patients without proteinuria. MATERIALS AND METHODS: Multicenter open-label, randomized controlled clinical trial including patients over 65 year-old with hypertension and CKD stages 3-4 without proteinuria...
March 19, 2024: Hipertensión y Riesgo Vascular
https://read.qxmd.com/read/38508876/is-proteinuria-an-important-fact-concerning-the-nephroprotective-effect-of-renin-angiotensin-system-inhibitors
#34
JOURNAL ARTICLE
J M Galceran
No abstract text is available yet for this article.
March 19, 2024: Hipertensión y Riesgo Vascular
https://read.qxmd.com/read/38508632/finerenone-cardiovascular-and-kidney-outcomes-by-age-and-sex-fidelity-post-hoc-analysis-of-two-phase-3-multicentre-double-blind-trials
#35
RANDOMIZED CONTROLLED TRIAL
Shweta Bansal, Maria E F Canziani, Rita Birne, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Peter Rossing, Luis M Ruilope, Alfredo E Farjat, Peter Kolkhof, Andrea Lage, Meike Brinker, Bertram Pitt
OBJECTIVES: This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex. DESIGN: FIDELITY post hoc analysis; median follow-up of 3 years. SETTING: FIDELITY: a prespecified analysis of the FIDELIO-DKD and FIGARO-DKD trials. PARTICIPANTS: Adults with type 2 diabetes and chronic kidney disease receiving optimised renin-angiotensin system inhibitors (N=13 026)...
March 19, 2024: BMJ Open
https://read.qxmd.com/read/38507510/kidney-renin-angiotensin-system-lost-in-a-ras-cascade
#36
JOURNAL ARTICLE
Steven D Crowley, L Gabriel Navar, Minolfa C Prieto, Susan B Gurley, Thomas M Coffman
Renin was discovered more than a century ago. Since then, the functions of the renin-angiotensin system in the kidney have been the focus of intensive research revealing its importance in regulation of renal physiology and in the pathogenesis of heart, vascular, and kidney diseases. Inhibitors of renin-angiotensin system components are now foundational therapies for a range of kidney and cardiovascular diseases from hypertension to heart failure to diabetic nephropathy. Despite years of voluminous research, emerging studies continue to reveal new complexities of the regulation of the renin-angiotensin system within the kidney and identification of nonclassical components of the system like the prorenin receptor (PRR) and ACE2 (angiotensin-converting enzyme 2), with powerful renal effects that ultimately impact the broader cardiovascular system...
April 2024: Hypertension
https://read.qxmd.com/read/38507492/an-evolutionarily-conserved-olfactory-receptor-is-required-for-sex-differences-in-blood-pressure
#37
JOURNAL ARTICLE
Jiaojiao Xu, Rira Choi, Kunal Gupta, Helen R Warren, Lakshmi Santhanam, Jennifer L Pluznick
Sex differences in blood pressure are well-established, with premenopausal women having lower blood pressure than men by ~10 millimeters of mercury; however, the underlying mechanisms are not fully understood. We report here that sex differences in blood pressure are absent in olfactory receptor 558 knockout (KO) mice. Olfr558 localizes to renin-positive cells in the kidney and to vascular smooth muscle cells. Female KOs exhibit increased blood pressure and increased pulse wave velocity. In contrast, male KO mice have decreased renin expression and activity, altered vascular reactivity, and decreased diastolic pressure...
March 22, 2024: Science Advances
https://read.qxmd.com/read/38507360/association-of-antihypertensives-and-parkinson-s-disease-in-a-primary-care-population-matched-for-underlying-diagnosis
#38
JOURNAL ARTICLE
Anette Schrag, Karel Kostev
PURPOSE: To examine the association of several antihypertensive medication classes with incidence of Parkinson's disease (PD), taking into account possible underlying conditions. METHODS: In a case-control study based on a large primary care database and including 21,981 PD cases and 21,981 non-PD controls matched for age, sex, and possible treatment indications associations with different antihypertensive medication groups, including diuretics, betablockers, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin-II receptor-blockers and PD were examined...
2024: PloS One
https://read.qxmd.com/read/38506079/indoxyl-sulphate-initiated-activation-of-cardiac-fibroblasts-is-modulated-by-aryl-hydrocarbon-receptor-and-nuclear-factor-erythroid-2-related-factor-2
#39
JOURNAL ARTICLE
Chiara Barisione, Daniela Verzola, Silvano Garibaldi, Paola Altieri, Anna Lisa Furfaro, Mariapaola Nitti, Giovanni Pratesi, Domenico Palombo, Pietro Ameri
In the last decade, extensive attention has been paid to the uremic toxin indoxyl sulphate (IS) as an inducer of cardiac fibroblast (cFib) activation and cardiac fibrosis in chronic kidney disease. At cellular level, IS engages aryl hydrocarbon receptor (AhR) and regulates many biological functions. We analysed how AhR inhibition by CH-223191 (CH) and overexpression of non-functional (dominant negative, DN) nuclear factor-erythroid-2-related factor 2 (NRF2), a transcription factor recruited by AhR, modulate the response of neonatal mouse (nm) cFib to IS...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38505676/protective-effects-of-limb-remote-ischemic-per-conditioning-on-the-heart-injury-induced-by-renal-ischemic-reperfusion-through-the-interaction-of-the-apelin-with-the-ras-inos-pathway
#40
JOURNAL ARTICLE
Sahar Janfeshan, Fatemeh Masjedi, Zeinab Karimi
INTRODUCTION: Remote ischemic conditioning upregulates endogenous protective pathways in response to ischemia-reperfusion injury. This study tested the hypothesis that limb remote ischemic per- conditioning (RIPerC) exerts cardioprotective effects via the renin-angiotensin system (RAS)/inducible nitric oxide synthase (iNOS)/apelin pathway. METHODS: Renal ischemia-reperfusion injury (I/R) was induced by bilateral occlusion of the renal pedicles for 60 minutes, followed by 24 hours of reperfusion; sham-operated rats served as controls...
2024: BioImpacts: BI
keyword
keyword
15763
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.